|
US4935343A
(en)
|
1986-08-08 |
1990-06-19 |
Syntex (U.S.A.) Inc. |
Monoclonal antibodies for interleukin-1β
|
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
|
AU2003208946A1
(en)
|
2002-02-28 |
2003-09-16 |
Eli Lilly And Company |
Anti-interleukin-1 beta analogs
|
|
CN1678634A
(zh)
*
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
|
JP4538461B2
(ja)
|
2003-01-24 |
2010-09-08 |
アプライド モレキュラー エボリューション，インコーポレイテッド |
ヒトＩＬ−１βアンタゴニスト
|
|
US20050282233A1
(en)
|
2004-03-05 |
2005-12-22 |
Ludwig Institute For Cancer Research |
Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
AR059066A1
(es)
*
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
BRPI0811466A2
(pt)
|
2007-05-07 |
2014-10-14 |
Medimmune Llc |
Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
JO2913B1
(en)
*
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
HRP20130042T1
(hr)
|
2008-06-06 |
2013-03-31 |
Xoma Technology Ltd. |
Postupci lijeäśenja reumatoidnog artritisa
|
|
RU2368359C1
(ru)
|
2008-07-22 |
2009-09-27 |
Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) |
Способ лечения возрастной макулярной дегенерации
|
|
US8268314B2
(en)
*
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
|
US8133979B2
(en)
*
|
2008-12-16 |
2012-03-13 |
Hoffmann-La Roche Inc. |
Antibodies against human angiopoietin 2
|
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
|
|
CN104474546A
(zh)
|
2010-08-13 |
2015-04-01 |
弗·哈夫曼-拉罗切有限公司 |
用于疾病治疗的针对IL-1β和IL-18的抗体
|
|
WO2012034039A2
(en)
|
2010-09-10 |
2012-03-15 |
Apexigen, Inc. |
Anti-il-1 beta antibodies and methods of use
|
|
WO2012125850A1
(en)
|
2011-03-16 |
2012-09-20 |
Amgen Inc. |
Fc variants
|
|
EP2726088B1
(en)
*
|
2011-06-29 |
2019-01-02 |
Amgen Inc. |
Predictive biomarker of survival in the treatment of renal cell carcinoma
|
|
SG11201408196RA
(en)
|
2012-06-28 |
2015-03-30 |
Molecular Partners Ag |
Designed ankyrin repeat proteins binding to platelet-derived growth factor
|
|
SI3495387T1
(sl)
*
|
2012-07-13 |
2021-12-31 |
Roche Glycart Ag |
Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
|
|
US20140093498A1
(en)
*
|
2012-09-28 |
2014-04-03 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
|
|
WO2014049100A1
(en)
*
|
2012-09-28 |
2014-04-03 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
|
|
AU2013342275B2
(en)
|
2012-11-08 |
2017-11-09 |
Clearside Biomedical, Inc. |
Methods and devices for the treatment of ocular diseases in human subjects
|
|
RU2015115956A
(ru)
|
2012-11-09 |
2017-01-10 |
Пфайзер Инк. |
Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
|
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
|
CA2904806C
(en)
*
|
2013-04-29 |
2021-11-23 |
F. Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
|
CN105611944A
(zh)
*
|
2013-12-20 |
2016-05-25 |
豪夫迈·罗氏有限公司 |
抗ang2抗体和cd40激动剂的组合疗法
|
|
CN110903398B
(zh)
*
|
2014-01-15 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
|
EP3218400A1
(en)
|
2014-11-10 |
2017-09-20 |
F. Hoffmann-La Roche AG |
Anti-pdgf-b antibodies and methods of use
|
|
JP2017537896A
(ja)
*
|
2014-11-10 |
2017-12-21 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
二重特異性抗体及び眼科に使用する方法
|
|
SG11201702550WA
(en)
|
2014-11-10 |
2017-04-27 |
Hoffmann La Roche |
ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
|
|
WO2016209972A1
(en)
*
|
2015-06-26 |
2016-12-29 |
Amgen Inc. |
Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
|
|
BR112019022074A2
(pt)
*
|
2017-06-02 |
2020-05-12 |
Boehringer Ingelheim International Gmbh |
Terapia de combinação anticâncer
|